Australasian College of Dermatologists 2017 E-Posters

Absolute and relative PASI over 1 year of treatment with ixekizumab (IXE): Descriptive analysis in patients with moderate-to-severe plaque psoriasis
Dr. Nicole Burkhardt
Acute generalised pustular psoriasis of pregnancy 
Dr. Eleni Anthony
Capecitabine exacerbates psoriasis in colon cancer patients. A case report
Dr. Francis Yap
Cardiovascular risk in psoriasis patients
Dr. Philippa Dickison
Clinical response and minimal disease activity with the physician global assessment and body surface area tool: Apremilast ESTEEM analysis
Dr. Alice Gottlieb
Efficacy and safety of ixekizumab (IXE) compared to ustekinumab (UST) in patients with moderate-to-severe plaque psoriasis: A randomised head-to-head trial
Dr. Nicole Burkhardt
Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3-VOYAGE 1 study
Dr. Andrew Blauvelt
First case report of ustekinumab and botulinum toxin A injections in a patient
Dr. Victoria Harris
Indirect comparison of ixekizumab (IXE) and secukinumab (SEC) using matched-adjusted indirect comparisons (MAIC)
Dr. Nicole Burkhardt
Innovation in delivery of a topical combination treatment (enstilar®) for psoriasis vulgaris
Mr Kasper Nørremark
Ixekizumab (IXE) treatment enables rapid improvements in health-related quality of life (HRQoL) and itch: Results from UNCOVER-2 and UNCOVER-3
Dr. Nicole Burkhardt
Psoriasis patients’ knowledge of comorbidities
Dr. Philippa Dickison
Secukinumab 300mgs is more efficacious than ustekinumab 90mgs: Analysis of patients with body weights over 100kg from the CLEAR study
Dr. Lynda Spelman
Secukinumab demonstrates sustained high efficacy and a tolerable safety profile in moderate-to-severe psoriasis patients through 4 years of treatment
Mr Eric Mate
Secukinumab in pregnancy: Outcomes from the global safety database
Dr. John Sullivan
Secukinumab is efficacious in clearing moderate-to-severe scalp psoriasis: 12 week results of a randomised phase IIIb study
Mr Eric Mate
Secukinumab provides faster, more sustained relief from psoriasis-related pain, itching, and scaling than ustekinumab in subjects with moderate-to-severe plaque psoriasis
Prof. Rod Sinclair
Secukinumab provides rapid and sustained reductions in dactylitis, enthesitis, and nail psoriasis in patients with psoriatic arthritis (PsA)
Dr. Peter Nash
Secukinumab provides sustained improvement in psoriatic arthritis in both anti‒TNF-naïve and anti-TNF exposed patients
Dr. Stephen Hall
Secukinumab shows significant efficacy in difficult‐to‐treat palmoplantar psoriasis: 1.5 year data from the GESTURE study
A/Prof Peter Foley
Secukinumab shows significant efficacy in nail psoriasis: Week 32 results from the TRANSFIGURE study
Dr. John Sullivan
Secukinumab treatment shows no evidence of increased mycobacterium tuberculosis infections: Findings from in vitro, in vivo and clinical investigations
Dr. Chris Barker
The development of generalised granuloma annulare during treatment for palmoplantar psoriasis with ustekinumab
Dr. Virginia Pilcher
The development of vitiligo while receiving ustekinumab therapy for chronic plaque psoriasis - a case series
Dr. Virginia Pilcher
≥156-week apremilast safety and tolerability in patients with moderate to severe psoriasis and cardiometabolic comorbidities: ESTEEM pooled analysis
Dr. Jennifer Cather
≥156-week apremilast safety in psoriasis and psoriatic arthritis patients: Pooled analysis of the ESTEEM and PALACE phase 3 trials
Dr. Jeffrey Crowley